Approval · Notice of Compliance 23366 · 2020
KAZANO: Notice of Compliance 23366
Issued March 19, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23366
- Date
- March 19, 2020
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KAZANO | Not yet assigned | — |
Medicinal ingredients
- METFORMIN HYDROCHLORIDE 500 MG per TAB
- ALOGLIPTIN BENZOATE 12.5 MG per TAB
- METFORMIN HYDROCHLORIDE 850 MG per TAB
- METFORMIN HYDROCHLORIDE 1,000 MG per TAB